Who is the new Chief Executive Officer at Dionysus Health?

Dionysus Health named Rashmi Raghavendra Chief Executive Officer, announced November 23, 2025.

Which similar companies made leadership changes around the same time?

Pacific Edge (November 27, 2025), RetinalGeniX Technologies (December 9, 2025), BrainScope (November 4, 2025) and Thyrocare Technologies (December 18, 2025) also announced leadership changes within 45 days of Dionysus Health.

Dionysus Health Appoints Rashmi Raghavendra as Chief Executive Officer

PRIVATENov 23, 2025

Position

Chief Executive Officer

Company

Dionysus Health

Rashmi Raghavendra

rraghavendra@dionysushealth.com

United StatesBiotechnologyHealth CareHealth Diagnostics

Description

Dionysus Health has announced the appointment of Rashmi Raghavendra as Chief Executive Officer. Raghavendra brings over 20 years of experience in digital health and diagnostics innovation, aiming to guide the company's transition from scientific validation to commercialization.

Quick answer

Dionysus Health Appoints Rashmi Raghavendra as Chief Executive Officer (November 23, 2025). Dionysus Health is based in United States.

Who is the new Chief Executive Officer at Dionysus Health?: Dionysus Health named Rashmi Raghavendra Chief Executive Officer, announced November 23, 2025.
What did Dionysus Health announce on November 23, 2025?: Dionysus Health has announced the appointment of Rashmi Raghavendra as Chief Executive Officer. Raghavendra brings over 20 years of experience in digital health and diagnostics innovation, aiming to guide the company's transition from scientific validation to commercialization.
What does Dionysus Health do?: Dionysus Health is a precision diagnostics company harnessing AI and epigenetics to predict and prevent postpartum depression before it starts.
Where is Dionysus Health based?: Dionysus Health is based in United States.
Which similar companies made leadership changes around the same time?: Pacific Edge (November 27, 2025), RetinalGeniX Technologies (December 9, 2025), BrainScope (November 4, 2025) and Thyrocare Technologies (December 18, 2025) also announced leadership changes within 45 days of Dionysus Health.

Source: Fundz verified event record.

Other recent leadership changes in Health Diagnostics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Pacific Edge Appoints James Vaughn as Chief Commercial Officer (November 27, 2025)
RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer (December 9, 2025)
BrainScope Appoints Matt Adams as Chief Executive Officer (November 4, 2025)
Thyrocare Technologies Appoints Dr Ramesh Kinha as Chief Operating Officer (December 18, 2025)
Epiminder Appoints Mark McLellan as Chief Financial Officer (October 21, 2025)
ImpriMed Appoints Valerie Goodwin-Adams as Chief Commercial Officer (October 14, 2025)

Who to call at Dionysus Health, and when

A new leader at Dionysus Health brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Dionysus Health raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Dionysus Health, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Dionysus Health. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Dionysus Health

Location

United States

About

Dionysus Health is a precision diagnostics company harnessing AI and epigenetics to predict and prevent postpartum depression before it starts. The company's proprietary blood test identifies a woman's risk as early as 24 weeks of pregnancy, using advanced molecular biomarkers and AI-driven pattern recognition to detect biological changes months before symptoms arise. Clinically validated in more than 600 participants with up to 90% predictive accuracy, the diagnostic has been supported by $14.5 million in non-dilutive funding from the National Institutes of Health (NIH) and the U.S. Department of Defense (DoD). Dionysus Health anticipates FDA Breakthrough Device designation in 2026 and full approval by 2027, with its first commercial pilots launching in 2025. Every year, postpartum depression affects one in five new mothers and costs the U.S. more than $14 billion, yet half of all cases go undiagnosed and untreated. Dionysus Health's mission is simple but profound: to make predictive maternal mental health screening the standard of care, improving outcomes for women, families, and society at large.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Dionysus Health changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans